tradingkey.logo

Pacific Biosciences of California Inc

PACB
1.770USD
-0.110-5.85%
收盘 12/26, 16:00美东报价延迟15分钟
534.28M总市值
亏损市盈率 TTM

Pacific Biosciences of California Inc

1.770
-0.110-5.85%

关于 Pacific Biosciences of California Inc 公司

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Pacific Biosciences of California Inc简介

公司代码PACB
公司名称Pacific Biosciences of California Inc
上市日期Oct 27, 2010
CEOHenry (Christian O)
员工数量575
证券类型Ordinary Share
年结日Oct 27
公司地址1305 O'brien Drive
城市MENLO PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94025
电话16505218000
网址https://www.pacb.com/
公司代码PACB
上市日期Oct 27, 2010
CEOHenry (Christian O)

Pacific Biosciences of California Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
696.81K
-17.96%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
110.00K
-17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
110.00K
-17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Mark Van Oene
Mr. Mark Van Oene
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jim R. Gibson
Mr. Jim R. Gibson
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
--
--
Ms. Kathy P. Ordonez
Ms. Kathy P. Ordonez
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
696.81K
-17.96%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
110.00K
-17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
110.00K
-17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Consumable revenue
18.93M
47.61%
Instrument revenue
14.15M
35.58%
Service And Other
6.68M
16.81%
地区USD
名称
营收
占比
North America
17.69M
44.48%
Asia Pacific
12.61M
31.72%
Europe (including the Middle East and Africa)
9.47M
23.81%
业务
地区
业务USD
名称
营收
占比
Consumable revenue
18.93M
47.61%
Instrument revenue
14.15M
35.58%
Service And Other
6.68M
16.81%

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
ARK Investment Management LLC
10.24%
SoftBank Group Corp
6.77%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.43%
Edmond de Rothschild Asset Management (France) S.A.
3.54%
其他
67.44%
持股股东
持股股东
占比
ARK Investment Management LLC
10.24%
SoftBank Group Corp
6.77%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.43%
Edmond de Rothschild Asset Management (France) S.A.
3.54%
其他
67.44%
股东类型
持股股东
占比
Investment Advisor
37.57%
Investment Advisor/Hedge Fund
10.88%
Holding Company
6.77%
Hedge Fund
3.17%
Individual Investor
1.16%
Corporation
1.16%
Research Firm
1.13%
Sovereign Wealth Fund
0.40%
Bank and Trust
0.15%
其他
37.61%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
566
166.98M
55.32%
-97.69M
2025Q2
600
214.62M
71.52%
-110.62M
2025Q1
629
227.30M
75.82%
-104.21M
2024Q4
625
258.31M
94.32%
-61.55M
2024Q3
618
231.32M
84.94%
-85.30M
2024Q2
629
240.26M
88.29%
-64.03M
2024Q1
637
265.38M
97.57%
-38.04M
2023Q4
643
276.71M
103.53%
-9.49M
2023Q3
631
258.82M
103.48%
-18.47M
2023Q2
639
248.61M
99.68%
-37.06M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
ARK Investment Management LLC
36.30M
12.08%
-180.28K
-0.49%
Jun 30, 2025
SoftBank Group Corp
20.45M
6.81%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.97M
6.65%
-470.54K
-2.30%
Jun 30, 2025
The Vanguard Group, Inc.
16.02M
5.33%
-197.42K
-1.22%
Jun 30, 2025
Edmond de Rothschild Asset Management (France) S.A.
13.37M
4.45%
-8.49M
-38.84%
Jun 30, 2025
Amova Asset Management Co., Ltd.
9.22M
3.07%
-346.88K
-3.63%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.72M
2.24%
+401.64K
+6.36%
Jun 30, 2025
State Street Investment Management (US)
5.75M
1.92%
-625.01K
-9.80%
Jun 30, 2025
Madrone Advisors, LLC
16.76M
5.58%
-6.63M
-28.34%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
ARK Genomic Revolution ETF
2.3%
iShares Genomics Immunology and Healthcare ETF
1.31%
Invesco NASDAQ Future Gen 200 ETF
0.96%
Global X Genomics & Biotechnology ETF
0.69%
ARK Innovation ETF
0.58%
AXS Green Alpha ETF
0.58%
WisdomTree BioRevolution Fund
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.07%
查看更多
ARK Genomic Revolution ETF
占比2.3%
iShares Genomics Immunology and Healthcare ETF
占比1.31%
Invesco NASDAQ Future Gen 200 ETF
占比0.96%
Global X Genomics & Biotechnology ETF
占比0.69%
ARK Innovation ETF
占比0.58%
AXS Green Alpha ETF
占比0.58%
WisdomTree BioRevolution Fund
占比0.48%
Invesco RAFI US 1500 Small-Mid ETF
占比0.09%
ProShares Ultra Nasdaq Biotechnology
占比0.08%
Invesco Nasdaq Biotechnology ETF
占比0.07%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Pacific Biosciences of California Inc的前五大股东是谁?

Pacific Biosciences of California Inc 的前五大股东如下:
ARK Investment Management LLC持有股份:36.30M,占总股份比例:12.08%。
SoftBank Group Corp持有股份:20.45M,占总股份比例:6.81%。
BlackRock Institutional Trust Company, N.A.持有股份:19.97M,占总股份比例:6.65%。
The Vanguard Group, Inc.持有股份:16.02M,占总股份比例:5.33%。
Edmond de Rothschild Asset Management (France) S.A.持有股份:13.37M,占总股份比例:4.45%。

Pacific Biosciences of California Inc的前三大股东类型是什么?

Pacific Biosciences of California Inc 的前三大股东类型分别是:
ARK Investment Management LLC
SoftBank Group Corp
BlackRock Institutional Trust Company, N.A.

有多少机构持有Pacific Biosciences of California Inc(PACB)的股份?

截至2025Q3,共有566家机构持有Pacific Biosciences of California Inc的股份,合计持有的股份价值约为166.98M,占公司总股份的55.32%。与2025Q2相比,机构持股有所增加,增幅为-16.20%。

哪个业务部门对Pacific Biosciences of California Inc的收入贡献最大?

在FY2025Q2,Consumable revenue业务部门对Pacific Biosciences of California Inc的收入贡献最大,创收18.93M,占总收入的47.61%。
KeyAI